These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2875 related articles for article (PubMed ID: 24684643)

  • 1. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
    Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
    J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
    Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
    Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
    Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
    PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
    Hong YD; Onukwugha E; Slejko JF
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
    Tencer T; Friedman HS; Li-McLeod J; Johnson K
    J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
    Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
    Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
    Kwong WJ; Diels J; Kavanagh S
    Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 144.